ReviewJournal of applied genetics2025
MicroRNA bioinformatics in precision oncology: an integrated pipeline from NGS to AI-based target discovery.
Review in Journal of applied genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Identification of a metastasis-associated prognostic gene signature in osteosarcoma through integrated bioinformatics and functional analysis.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Article
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite the growing recognition of microRNAs (miRNAs) as critical biomarkers in cancer, current approaches to their analysis remain fragmented, disjointed, and poorly integrated with emerging computational advances. This lack of cohesion limits progress toward reproducible and clinically actionable biomarker discovery. To address this unmet need, we present a review that unifies the latest findings and tools in bioinformatics, machine learning (ML), and large language models (LLMs) for miRNA analysis in oncology, thereby bridging a significant methodological gap in the field. We begin by critically synthesizing, benchmarking, and evaluating algorithms, including miRDeep2 and DIANA-miRPath, within a functional pipeline that spans next-generation sequencing (NGS) data processing to multi-omics integration. Building on this foundation, we review ML-augmented layers incorporating supervised and deep learning (DL) algorithms, specifically support vector machines (SVMs), convolutional neural networks (CNNs), and recurrent neural networks (RNNs), to enable robust miRNA signature identification, classification, and target prediction. Furthermore, we explore the integration of generative models and LLMs to support hypothesis generation and enhance reproducibility in biomarker discovery workflows. This comprehensive framework enhanced with artificial intelligence (AI) is contextualized through cancer-specific datasets, with particular emphasis on translational applications for early detection, prognosis, and therapy selection. By systematically organizing fragmented methodologies into a scalable and reproducible pipeline, our work provides a strategic roadmap to accelerate the development of miRNA-based precision cancer.
Indexed as
Identifiers
41168533What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.